Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 4,560 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: assessment only control Clear all

Conditions: Type 2 Diabetes Mellitus, Diabetic Peripheral Neuropathy
Interventions: Exenatide, Glargine; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 70 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Sacroiliac Joint Dysfunction
Interventions: Not listed
Lead sponsor: Coastal Orthopedics & Sports Medicine; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Bradenton, Florida

Conditions: Dental Caries
Interventions: C16G2 Varnish, Placebo Varnish; Drug
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 3
States / cities: Kalispell, Montana • Bedford, Texas • Irving, Texas

Conditions: Human Immunodeficiency Virus (HIV)
Interventions: Budigalimab, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Bakersfield, California • Los Angeles, California • San Francisco, California + 5 more

Conditions: COVID-19
Interventions: COVID-HIGIV, Placebo (saline); Biological · Other
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Cystic Fibrosis
Interventions: Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge, Olfactory Function Testing, Survey Completion; Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Healthy
Interventions: 0.5mg AZ-010; placebo, 1mg AZ-010, 3mg AZ-010, AZ-010 1mg, IV Granisetron 1mg, Placebo; Combination Product · Drug · Other
Lead sponsor: Nova Pneuma Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Actinic Keratosis
Interventions: Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle containing excipients only (VEH) without active ingredient, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E; Drug · Other · Device
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 12
States / cities: Fremont, California • Aventura, Florida • Rolling Meadows, Illinois + 9 more

Conditions: Heart Failure, Kidney Disease
Interventions: TRV120027, Normal Saline; Drug
Lead sponsor: Trevena Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Orlando, Florida • Minneapolis, Minnesota • Durham, North Carolina + 1 more

Conditions: Health Risk Behaviors, Risk Reduction Behavior
Interventions: Online and Text Messaging Intervention; Behavioral
Lead sponsor: University of North Texas Health Science Center; Other
Eligibility: 18 Years to 24 Years
Enrollment: 162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions: Quadrivalent VLP Vaccine, Fluarix Quadrivalent® Comparator Vaccine; Biological
Lead sponsor: Medicago; Industry
Eligibility: 65 Years and older
Enrollment: 12,794 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 50
States / cities: Mobile, Alabama • Tempe, Arizona • Banning, California + 42 more

Conditions: Lung Transplantation, Chronic Lung Disease, Muscle Weakness, Rehabilitation
Interventions: IMT- Intervention group, IMT- Placebo group; Device
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Critical Illness
Interventions: ASSIST, Attention-Control; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Jaw Fractures, Infection
Interventions: Antibiotic treatment (Unasyn or Cleocin), Antibiotic treatment (Augmentin or Cleocin), Control Group; Drug · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Crohn Disease
Interventions: Icotrokinra, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,092 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 64
States / cities: Chandler, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 51 more

Conditions: Nonalcoholic Steatohepatitis (NASH)
Interventions: NGM282, Placebo; Biological · Other
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 17
States / cities: Chandler, Arizona • Tucson, Arizona • Los Angeles, California + 13 more

Conditions: Pulmonary Embolism, Thrombotic Disease
Interventions: DS-1040b, Placebo, Enoxaparin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 15
States / cities: Mobile, Alabama • Beverly Hills, California • San Diego, California + 12 more

Conditions: Loneliness, Older Adults, fMRI, Emotions, EEG, Digital Intervention, Meditation
Interventions: intervention, waitlist control, No Interventions; Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 60 Years to 120 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy
Interventions: Pirtobrutinib, Placebo, Moxifloxacin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: Methamphetamine Abuse
Interventions: normal saline, ch-mAb7f9; Biological
Lead sponsor: InterveXion Therapeutics, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Primary Immune Deficiency
Interventions: GC5107; Biological
Lead sponsor: GC Biopharma Corp; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Aurora, Colorado • Centennial, Colorado • Dallas, Texas + 2 more

Conditions: Refractory Chronic Cough
Interventions: 3 mg NOC-100 (via nebulizer), 1 mg NOC-110 (via DPI) [1x 1 mg capsule], 3 mg NOC-110 (via DPI), Placebo (via DPI), 6 mg NOC-110 (via DPI), Placebo (via DPI) [2x Placebo capsules]; Drug
Lead sponsor: Nocion Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 3
States / cities: Phoenix, Arizona • Leesburg, Florida • Winter Park, Florida

Conditions: Low Back Pain
Interventions: Lumbar Interlaminar Epidural, Lumbar Interlaminar Epidural injection; Procedure
Lead sponsor: Pain Management Center of Paducah; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Paducah, Kentucky

Conditions: Healthy Volunteer, Opioid-use Disorder
Interventions: INDV-2000, Placebo, SUBOXONE® sublingual film; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Baltimore, Maryland • DeSoto, Texas • San Antonio, Texas

Search by objective public record fields.

Evaluation of Exenatide in Patients With Diabetic Neuropathy

Radiofrequency Nerve Ablation Versus Sham to Treat Chronic Low Back Pain Caused by Sacroiliac Joint Dysfunction

A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Dental Subjects

Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)

A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults

Impact of Highly Effective Modulator Therapy on the Cystic Fibrosis Microbiome

Staccato® Granisetron Single Dose PK

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp

Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction

Enhancing Quality in Protective Strategies

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

Inspiratory Muscle Training Immediately After Lung Transplantation

Self-Management Behaviors of Caregivers of the Chronically Critically Ill

The Evaluation of Postoperative Antibiotics in Non-Infected Mandible Fractures

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism

Dynamic Neural Systems Underlying Social-emotional Functions in Older Adults

A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants

Safety Study of Ch-mAb7F9 for Methamphetamine Abuse

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

Treatment of Chronic Low Back and Lower Extremity Pain

Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder